Jane Gross, PhD has been providing strategic direction in drug discovery and development of therapeutics for the treatment of autoimmune diseases and cancer for the last 20 years. Dr. Gross has a strong track record working in the biotechnology field developing new therapeutics to help treat patients with devastating autoimmune diseases. Most recently, Dr. Gross serves as Vice President of Research and Non-Clinical Development at Emergent BioSolutions in Seattle Washington where she works on new therapeutics that use the immune system to fight disease. Prior to this Dr. Gross led research efforts at ZymoGenetics, directing a team in the development of atacicept, a novel receptor fusion protein that helped efforts in the approval of benlysta the first new drug for systemic lupus erythematosus in over forty years.
Dr. Gross earned her Ph.D in Immunology at the University of California Berkeley under Dr. James P. Allison and her Bachelors of Science in Physiology and Child Development from the University of California, Davis. She completed her post-doctoral fellow in Immunology at the University of Washington under Dr. Roger M. Perlmutter MD, Ph.D. She is a frequent speaker at conferences and events around the world, and has over 20 publications.
Throughout her career, Dr. Gross has been active in promoting the sciences and has served in organizations for patient advocacy. She currently serves on the Board of Director’s for the Puget Sound Blood Center and is a member of the Autoimmune Advocacy Alliance. She has been an active member of Women in Biotechnology, the Association of Women in Science and the American Association for Immunologists. Dr. Gross has made a commitment to foster and support science education of our youth by serving on committees that advocate for science education in our schools.